Replenix
Replenix, licence 80088543: active licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
Natural health product licensed in Canada
- Other names
- Replenix Acne Solutions
- Licence holder
- Topix Pharmaceuticals, Inc.
- NPN or DIN-HM
- 80088543
- Status
- Active licence
- Licence date
- 2 October 2018
- Revision date
- Not provided
- Form
- Serviette, traité
- Route of administration
- Topique
- Application type
- Officinale
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
Medicinal composition not provided.
Non-medicinal ingredients
Alcool dénaturé, NA, EDTA de sodium, Acide glycolique, Aqua, Poly(sorbate) 20, Imidazolidinyl urée, Hydroxyde d'ammonium, Benzoate de sodium, Acétone
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Sous-population S/O | Not specified | Not specified | Not specified |
Uses authorised in Canada
For the treatment of acne.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Précautions et mises en garde
For external use only. Keep out of reach of children. If swallowed, call a Poison Control Centre or get medical help right away. Skin irritation and dryness are more likely to occur when using another topical acne product at the same time. If irritation occurs, use only one product at a time. Avoid contact with eyes; if contact occurs, rinse thoroughly with water. For more severe cases, and/or if improvement is not apparent within 6-8 weeks, consult a health care professional. Use only as directed. If irritation persists, discontinue use and consult a physician. It is recommended that prior to exposure to the sun, users cover areas where AHAs have been applied with sunscreen. Contact of the product with the skin must be of limited frequency or duration.
Source
Official Health Canada record, licence 80088543
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.